Life Biosciences and Forge Biologics to Partner in Novel Gene Therapies cGMP Manufacturing for Aging-Related Diseases

Kadeja Johnson
10 May 2023
Collaborations, Mergers & Acquisitions
Gene Therapy
Forge Biologics, Forge, to source cGMP manufacturing and development services for Life Biosciences’ novel adeno-associated virus (AAV) gene therapy platform for aging-related diseases.

“We believe we’re on the cusp of revolutionizing medicine with our cellular rejuvenation capabilities across a range of aging-related diseases, including ophthalmic disorders that involve retinal ganglion cell dysfunction,” highlighted Jerry McLaughlin, CEO of Life Biosciences.

Life Biosciences, Life Bio, a biotechnology company advancing cellular rejuvenation technologies to restore health for patients through reversing the diseases of aging and injury and Forge, a genetic medicines manufacturing organization announced a manufacturing partnership to help advance Life Bio’s partial reprogramming platform.

“Life Bio is an emerging leader in the development of novel therapies for aging-related diseases, and we are thrilled to serve as their cGMP manufacturing partner to help advance the manufacturing of AAV for their innovative cellular rejuvenation technology, which has the potential to benefit millions of aging patients worldwide,” stated Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge.

How are you enjoying this news article? Let us know your thoughts, here >>


The partnership will encompass Life Bio’s partial epigenetic reprogramming platform to combat aging-related diseases, including its lead program targeting ophthalmic indications. Forge will supply its adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing and analytical services to Life Bio. All development and AAV manufacturing procedures will take place at the Hearth, Forge’s 200,00 square foot gene therapy facility in Columbus, Ohio.

McLaughlin expressed the delight “to be working with the Forge team, whose expertise in gene therapy manufacturing is unmatched.”

The company will utilize Forge’s platform processes including its proprietary HEK293 suspension Ignition Cells™ and pEMBR™ adenovirus helper plasmid.

“We are confident our partnership with Forge will have a tremendous impact on our ability to enhance the speed and quality with which we can manufacture our therapeutic candidates as we progress toward the first human clinical trials and continue to develop treatments to reverse diseases of aging by restoring cells to a more youthful state.”

Source: Forge Biologics Press Release

While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to